GENE ONLINE|News &
Opinion
Blog

Acute Myeloid Leukemia
A $230M Deal for New Leukemia Drug Awaits FDA
2022-08-03
As BIO 2021 Approaches, Taiwan’s DCB Reveals Competitive Bio-Innovations to Watch Out For
2021-06-11
Bluebird Bio Temporarily Suspends Sickle Cell Trials Following Cancer Diagnosis in Two Patients
2021-02-18
FDA Approves Venetoclax Combination for New Acute Myeloid Leukemia Cases
2020-10-19
Bristol Myers Squibb Notches Key Regulatory Win for Oral Formulation of Epigenetic Modifier
2020-09-06
Bristol-Myers-Squibb Anticipates FDA Approval for CC-486 as a Treatment for Acute Myeloid Leukemia
2020-08-30
ASGCT20: Intellia Presents Data on Two of its CRISPR-Based Novel Therapeutic Candidates
2020-05-16
Gilead Strikes US$ 4.9B Takeover Deal of Forty Seven
2020-03-02
Weekly in Asia|Oct-2
2019-10-23
Weekly in Asia 20190602-0608
2019-06-11
Gilteritinib becomes first FLT3 targeted therapy for relapsed AML
2018-12-04
LATEST
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top